导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -7.75% | 3615/4773 |
| 近一周 | -2.59% | 2618/5462 |
| 近一月 | -1.82% | 1054/5421 |
| 近一季 | -0.93% | 909/5209 |
| 近半年 | -5.01% | 2702/4920 |
| 近一年 | -11.23% | 3486/4366 |
| 近两年 | 35.52% | 2075/2954 |
| 近三年 | 31.60% | 989/2253 |
| 成立以来 | 3.00% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.48% 3847/4961 |
-9.26% 3948/5312 |
- - |
- - |
| 2025 | 27.32% 1567/4813 |
15.68% 162/3635 |
3.78% 946/4076 |
11.87% 3120/4524 |
-5.20% 3522/4813 |
| 2024 | 22.77% 369/3463 |
-1.52% 1237/2808 |
10.17% 43/3014 |
16.47% 1448/3129 |
-2.84% 2191/3463 |
| 2023 | -12.82% 1509/2656 |
0.15% 1756/2280 |
-0.80% 419/2385 |
-8.15% 1668/2515 |
-4.46% 1041/2655 |
| 2022 | -5.37% 118/2207 |
-7.93% 262/1919 |
5.96% 804/2016 |
-14.17% 1039/2113 |
13.02% 111/2208 |
| 2021 | -12.13% 1122/1822 |
4.91% 129/1255 |
0.52% 1097/1330 |
-11.73% 1276/1466 |
-5.60% 1521/1822 |
| 2020 | -7.16% 986/1250 |
-14.34% 960/1028 |
3.77% 929/1067 |
-6.57% 1124/1164 |
11.79% 519/1184 |
| 2019 | 11.60% 727/1092 |
9.17% 726/739 |
1.37% 131/788 |
-5.51% 797/850 |
6.72% 561/918 |
| 2018 | - - |
- - |
1.38% 23/631 |
0.61% 149/660 |
-6.50% 47/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方恒生指数ETF联接C VS. 长安沪深300非周期A(740101) |